ImmunityBio (IBRX) Cash from Operations (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Cash from Operations of 75400000.0 for Q1 2026, up 12.23% year-over-year from 67184285.86 in Q1 2025, and down 7.19% quarter-over-quarter from 70342000.0 in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Cash from Operations (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Cash from Operations for 13 consecutive years, with 75400000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 12.23% year-over-year to 75400000.0; the TTM figure through Mar 2026 stood at 294395000.0 (up 20.47% YoY), while the FY2025 annual figure was 304900000.0, up 22.07% from the prior year.
- Cash from Operations declined to 75400000.0 in Q1 2026 per IBRX's latest filing, from 70342000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 68858000.0 in Q3 2025 and bottomed at 115271000.0 in Q4 2023.
- Historically, Cash from Operations has averaged 86811882.35 across 5 years, with a median of 85144000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 31.12% — and 2025, when it jumped 30.28%.
- ImmunityBio's Cash from Operations stood at 90727000.0 in 2022, then fell by 27.05% to 115271000.0 in 2023, then advanced by 26.14% to 85144000.0 in 2024, then grew by 17.38% to 70342000.0 in 2025, then slipped by 7.19% to 75400000.0 in 2026.
- Business Quant data shows IBRX's Cash from Operations at 75400000.0 in Q1 2026, 70342000.0 in Q4 2025, and 68858000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | ImmunityBio | 8.51 Bn | 8.15 Bn | 50.94 Mn | -66.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -66.50 Mn |
| Mar 31, 2026 | -75.40 Mn |
| Dec 31, 2025 | -70.34 Mn |
| Sep 30, 2025 | -68.95 Mn |
| Jun 30, 2025 | -79.75 Mn |
| Mar 31, 2025 | -85.91 Mn |
| Dec 31, 2024 | -85.14 Mn |
| Sep 30, 2024 | -98.76 Mn |
| Jun 30, 2024 | -100.35 Mn |
| Mar 31, 2024 | -106.98 Mn |
| Dec 31, 2023 | -115.27 Mn |
| Sep 30, 2023 | -87.40 Mn |
| Jun 30, 2023 | -79.77 Mn |
| Mar 31, 2023 | -84.31 Mn |
| Dec 31, 2022 | -90.73 Mn |
| Sep 30, 2022 | -80.60 Mn |
| Jun 30, 2022 | -91.25 Mn |
| Mar 31, 2022 | -74.93 Mn |
| Dec 31, 2021 | -71.64 Mn |
| Sep 30, 2021 | -72.72 Mn |